MX2014001933A - Ansolvatos de sal de noribogaina. - Google Patents

Ansolvatos de sal de noribogaina.

Info

Publication number
MX2014001933A
MX2014001933A MX2014001933A MX2014001933A MX2014001933A MX 2014001933 A MX2014001933 A MX 2014001933A MX 2014001933 A MX2014001933 A MX 2014001933A MX 2014001933 A MX2014001933 A MX 2014001933A MX 2014001933 A MX2014001933 A MX 2014001933A
Authority
MX
Mexico
Prior art keywords
ansolvates
noribogaine
noribogaine salt
solvated
salt ansolvates
Prior art date
Application number
MX2014001933A
Other languages
English (en)
Inventor
Richard D Gless
William C Schinzer
Original Assignee
Demerx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47881233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014001933(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Demerx Inc filed Critical Demerx Inc
Publication of MX2014001933A publication Critical patent/MX2014001933A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ansolvatos estables de sal de noribogaina son útiles para la preparación de composiciones farmacéuticas y para aliviar el dolor nociceptivo en un paciente. Dichos ansolvatos se pueden preparar por formación de suspensión de formas solvatadas, preferiblemente clorhidrato de noribogaina solvatado de MeOH en EtOH/agua.
MX2014001933A 2011-09-15 2012-09-14 Ansolvatos de sal de noribogaina. MX2014001933A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535300P 2011-09-15 2011-09-15
PCT/US2012/055597 WO2013040471A2 (en) 2011-09-15 2012-09-14 Noribogaine salt ansolvates

Publications (1)

Publication Number Publication Date
MX2014001933A true MX2014001933A (es) 2014-03-27

Family

ID=47881233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001933A MX2014001933A (es) 2011-09-15 2012-09-14 Ansolvatos de sal de noribogaina.

Country Status (18)

Country Link
US (4) US9040520B2 (es)
EP (1) EP2755658A4 (es)
KR (2) KR20140062472A (es)
CN (2) CN103857397B (es)
AU (1) AU2012308274B2 (es)
BR (1) BR112014005064A2 (es)
CA (1) CA2845007C (es)
CL (1) CL2014000506A1 (es)
CO (1) CO6970589A2 (es)
HK (1) HK1199840A1 (es)
IL (1) IL230940B (es)
MX (1) MX2014001933A (es)
PE (1) PE20142353A1 (es)
RU (1) RU2014105881A (es)
SG (1) SG2014011811A (es)
TW (2) TW201726676A (es)
WO (1) WO2013040471A2 (es)
ZA (1) ZA201401268B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765737B1 (en) * 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9394294B2 (en) * 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
MX2013000733A (es) 2010-07-23 2013-05-30 Demerx Inc Composiciones de noribogaina.
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
BR112014005064A2 (pt) 2011-09-15 2017-04-04 Demerx Inc não solvatos de sal de norigobaína
CA2855994A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
CA3142817A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013112673A1 (en) 2012-01-25 2013-08-01 Demerx, Inc. Synthetic voacangine
US9783535B2 (en) 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
KR102293060B1 (ko) 2013-03-15 2021-08-23 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG11201507453VA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2942638A1 (en) 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
AU2014237340C1 (en) 2013-03-15 2018-11-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
RS61653B1 (sr) 2014-02-07 2021-04-29 Global Blood Therapeutics Inc Kristalni polimorfni oblik slobodne baze 2-hidroksi-6-((2-(1-izopropil-1h-pirazol-5-il)piridin-3-il)metoksi)benzaldehid
JP2017509612A (ja) 2014-02-18 2017-04-06 デメルクス，インコーポレイテッド 薬物中毒の急性および長期間での治療方法。
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US9345711B2 (en) 2014-02-18 2016-05-24 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
EP3223906B1 (en) 2014-11-26 2021-01-06 DemeRx, Inc. Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
MX2018006832A (es) 2015-12-04 2018-11-09 Global Blood Therapeutics Inc Regimenes de dosificacion de 2-hidroxi-6-((2-(1-isopropil-1h-piraz ol-5-il)-piridin-3-il)-metoxi)-benzaldehido.
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
WO2023150547A2 (en) * 2022-02-01 2023-08-10 Caamtech, Inc. Psychedelic compounds and their therapeutic uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2813873A (en) * 1957-11-19 Derivatives of the ibogaine alkaloids
GB789870A (en) * 1955-10-10 1958-01-29 Gobey Lab Alkaloid derivatives
ES2264562T3 (es) * 1994-07-25 2007-01-01 Nda International, Inc. Uso de derivados de noribogaina para tratar la dependencia quimica en mamiferos.
US5591738A (en) * 1994-10-14 1997-01-07 Nda International, Inc. Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
CA2302754C (en) * 1997-09-04 2011-11-08 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
RU2005117630A (ru) 2002-11-08 2006-01-20 Дов Фармасьютикал, Инк. (Us) Полиморфы гидрохлорида бицифадина
AU2007209992A1 (en) * 2006-01-31 2007-08-09 Thallion Pharmaceuticals Inc. Crystalline forms of a farnesyl dibenzodiazepinone
MX2013000733A (es) * 2010-07-23 2013-05-30 Demerx Inc Composiciones de noribogaina.
EP2481740B1 (en) * 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
BR112014005064A2 (pt) 2011-09-15 2017-04-04 Demerx Inc não solvatos de sal de norigobaína

Also Published As

Publication number Publication date
US9040520B2 (en) 2015-05-26
US20160108043A1 (en) 2016-04-21
CA2845007A1 (en) 2013-03-21
ZA201401268B (en) 2016-11-30
TWI588145B (zh) 2017-06-21
US9617265B2 (en) 2017-04-11
BR112014005064A2 (pt) 2017-04-04
CL2014000506A1 (es) 2014-08-22
EP2755658A2 (en) 2014-07-23
KR102381792B1 (ko) 2022-04-01
TW201726676A (zh) 2017-08-01
PE20142353A1 (es) 2015-01-10
KR20200115661A (ko) 2020-10-07
IL230940B (en) 2022-04-01
CN105949193A (zh) 2016-09-21
IL230940A0 (en) 2014-03-31
AU2012308274A1 (en) 2014-02-27
US20170022193A1 (en) 2017-01-26
CO6970589A2 (es) 2014-06-13
KR20140062472A (ko) 2014-05-23
US20130072472A1 (en) 2013-03-21
US20170022194A1 (en) 2017-01-26
SG2014011811A (en) 2014-05-29
EP2755658A4 (en) 2015-03-18
CA2845007C (en) 2020-09-29
AU2012308274B2 (en) 2017-08-17
RU2014105881A (ru) 2015-10-20
WO2013040471A2 (en) 2013-03-21
TW201313720A (zh) 2013-04-01
CN103857397A (zh) 2014-06-11
WO2013040471A3 (en) 2013-05-10
NZ620948A (en) 2016-10-28
CN103857397B (zh) 2016-08-17
HK1199840A1 (en) 2015-07-24

Similar Documents

Publication Publication Date Title
MX2014001933A (es) Ansolvatos de sal de noribogaina.
IL276414A (en) A pyruvate kinase activator for therapeutic use
HK1246783A1 (zh) 可用於治療的噠嗪衍生物
EP2691096B8 (en) Pouch containing nicotine in free salt form
GB201117313D0 (en) Bacterium for use in medicine
KR101856921B9 (ko) 이온 주입에 사용하기 위한 패키지된 가스 혼합물
UA111186C2 (uk) Способи та композиції для одержання норибогаїну з воакангіну
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
IL215399A (en) Methods for making pharmaceutical ingredients
MX2014002552A (es) Compuesto pirazol y su uso farmaceutico.
HUE054072T2 (hu) A nitrokatecholok adagolási rendje
IL231383A0 (en) History of imidazole amines, their preparation and pharmaceutical preparations containing them
IN2014DN00180A (es)
MX356801B (es) Incremento en la biodisponibilidad de fármacos en la terapia con naltrexona.
EP2609933A4 (en) AQUEOUS COMPOSITION FOR ADMINISTRATION
ZA201309559B (en) Comptothecin derivative, method for preparing same, pharmaceutical composition and use thereof
EP2751141A4 (en) STABLE PACE4 INHIBITORS BASED ON PEPTIDE
IL228439A0 (en) Gallium compounds, medical preparations and methods of use
ZA201306419B (en) Compositions and methods for separating,characterizing and administering soluble selenoglycoproteins
EP2738176A4 (en) WATER-SOLUBLE CAMPTOTHECIN DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREFOR AND ITS USE
EP2697239A4 (en) N-SUBSTITUTED MANNOSAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
EP2725024A4 (en) AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE
GB201206968D0 (en) Compositions for growth and vigour in ornamentals
EP2701718A4 (en) LANTIBIOTIC NAI-802, PHARMACEUTICALLY ACCEPTABLE SALTS, ITS COMPOSITIONS, AND USES THEREOF
SG2014010433A (en) Stable compositions and methods for preparing the same